Acorda Therapeutics to Present at JMP Healthcare Conference

HAWTHORNE, N.Y.--(BUSINESS WIRE)--

Acorda Therapeutics, Inc. (ACOR) today announced that Jane Wasman, Chief, Strategic Development and General Counsel, will present at the JMP Healthcare Conference on Thursday, July 12, 2012 at 2:30 pm ET at the Peninsula Hotel in New York.

A live audio webcast of the presentation can be accessed under Investor Events in the Investor section of the Acorda website at http://www.acorda.com, or you may use the link:

http://wsw.com/webcast/jmp18/acor/

Please log in approximately 5 minutes before the scheduled time of the presentation to ensure a timely connection. An archived version of the webcast will be available until August 12, 2012 on the Investors section of http://www.acorda.com.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions.

Acorda markets AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. AMPYRA is marketed outside the United States as FAMPYRA (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license from Alkermes Pharma Ireland Limited.

The Company also markets ZANAFLEX CAPSULES (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity. Acorda also receives sales royalties on tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES distributed by Watson Pharmaceutics, Inc. under its agreement with Acorda.

Acorda is developing an industry-leading pipeline of novel neurological therapies. The Company is studying AMPYRA to improve a range of functional impairments caused by MS, as well as its use in other neurological conditions, including cerebral palsy and chronic stroke. In addition, Acorda is developing clinical stage compounds AC105 for acute treatment of spinal cord injury and GGF2 for treatment of heart failure.GGF2 is also being investigated in preclinical studies as a treatment for neurological conditions such as stroke and spinal cord injury. Additional preclinical programs include rHIgM22, a remyelinating monoclonal antibody for the treatment of MS, and chondroitinase, an enzyme that encourages nerve plasticity in spinal cord injury.

The rest is here:
Acorda Therapeutics to Present at JMP Healthcare Conference